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Improved Survival after Pulmonary Metastasectomy for Soft
Tissue Sarcoma
Jarrod D. Predina, BA,* Matthew M. Puc, MD,* Meredith R. Bergey, MSc, MPH,†
Seema S. Sonnad, PhD,† John C. Kucharczuk, MD,* Arthur Staddon, MD,‡ Larry R. Kaiser, MD,*
and Joseph B. Shrager, MD§
Introduction: Survival after pulmonary metastasectomy for soft
tissue sarcoma (STS) has been lower than in osteosarcoma (14–40%
versus 40–50%). With improved patient selection criteria and ad-
vanced chemotherapy agents, we hypothesized that survival after
metastasectomy for STS has improved in recent years.
Methods: Retrospective study of 48 patients undergoing pulmonary
metastasectomy for STS between 1995 and 2007. Potential predic-
tors of overall survival and disease-free survival (DFS) were exam-
ined using the log-rank test or Cox regression. Multivariate analysis
was conducted using Cox regression.
Results: Overall survival after initial metastasectomy was 67% and
52% at 3 and 5 years, respectively; DFS was 17% and 10% at 3 and
5 years. Univariate analysis indicated that2 pulmonary metastases
(p 0.03), diameter of largest metastasis2 cm (p 0.09), and the
absence of extrapulmonary metastases (p  0.10) were associated
with longer overall survival. Absence of extrapulmonary metastases
(p 0.07) and smaller size of the largest pulmonary metastasis (p
0.06) were associated with longer DFS. Before 2001, 46.7% of
patients received adjuvant chemotherapy versus 72.7% after (p 
0.10). Neither use of chemotherapy nor chemotherapy type was
related to overall survival or DFS.
Conclusion: Five-year overall survival is substantially higher after
pulmonary metastasectomy for STS in our study relative to previ-
ously published results (52% versus 14–40%). This improvement
does not seem to be the result of greater use of, or newer, chemo-
therapeutic regimens. Among potential explanations, improved pa-
tient selection is the most likely factor.
Key Words: Soft tissue sarcoma, Pulmonary metastases, Chemo-
therapy, Surgery.
(J Thorac Oncol. 2011;6: 913–919)
Soft tissue sarcomas (STSs) are a diverse group of malignan-cies which are diagnosed in approximately 8000 patients
each year in the United States.1,2 Distant metastases occur in
approximately 20 to 50% of patients, with the lung being the
primary metastatic site.1,3,4 Pulmonary metastasectomy is a well-
accepted intervention that seems to provide the only opportunity
for patients with lung metastases to obtain long-term survival.5–7
Nonrandomized studies evaluating the use of pulmonary
metastasectomy for patients with STS report overall 5-year
survival rates ranging from 15 to 40%.5,8–14 Similar studies
evaluating pulmonary metastasectomy for patients with osteo-
sarcoma (OS) report 5-year survival rates ranging from 40 to
50%.15–17 The lower success for patients with STS has been
attributed to various causes, including less effective adjuvant
chemotherapy for STS when compared with OS and the greater
difficulty palpating small STS versus OS nodules. Over the last
decade, doxorubicin-ifosfamide (D/I)-based regimens have
emerged as the adjuvants of choice for metastatic STS.18,19 Data
supporting the use of adjuvant therapy, however, have been
conflicting with some reports documenting positive effects20 but
others describing little to no influence.12,21,22
Given the lower survival after pulmonary metastasectomy
for patients with STS, considerable effort has been placed in
identifying candidates who would be most likely to benefit from
resection. Several prognostic indicators have been associated
with longer survival including fewer pulmonary metastases,
smaller size of pulmonary metastases, tumor histology, complete
resection of pulmonary disease, prolonged disease-free interval
(DFI), absence of extrapulmonary metastases, younger age, and
use of perioperative chemotherapy.2,4–7,10–14,23
We retrospectively reviewed our experience with metas-
tasectomy for STS to evaluate the role of pulmonary metasta-
sectomy in this era of improved patient selection and putatively
more effective chemotherapy protocols. With the advent of these
advancements, we hypothesized that survival time after metas-
tasectomy for STS will have improved in recent years.
PATIENTS AND METHODS
Subject Selection
Patients were identified using the Thoracic Surgery
Database within the University of Pennsylvania Health Sys-
tem (UPHS). Fifty-six patients who had undergone one or
more pulmonary resections for histologically confirmed pul-
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monary metastases of STS between 1995 and 2007 were
initially identified. The few patients who underwent pulmo-
nary resection with active extrapulmonary disease (n  2)
were excluded from analysis. Six additional patients were
excluded as follow-up data could not be obtained.
Prognostic Variables and Data Acquisition
Prognostic variables were abstracted from the medical
records. Variables included age at diagnosis, year of surgery,
sarcoma histological variant, size of largest pulmonary me-
tastasis, number of lung metastases (as proven by pathology),
lymph node involvement, history of resected extrapulmonary
metastases, and history of successfully treated recurrence at
the primary site. Chemotherapy regimen was noted if used at
any point after the diagnosis of pulmonary disease. Proce-
dural details and postoperative course were also documented.
All bilateral procedures, including staged bilateral thoracot-
omies occurring within 6 weeks of one another, were con-
sidered as a single intervention in the analysis.
Survival and disease status information were obtained
from the most recent UPHS medical record. If the most recent
record available was greater than 6 months before the time of
data collection or the patient maintained follow-up outside
UPHS, the patient/family was contacted and requisite infor-
mation was obtained by a standardized phone interview. If
follow-up data could not be obtained within 6 months of data
collection, patient data were obtained from the last docu-
mented follow-up, and the patient was appropriately censored
during survival analysis. Dates of death were determined
using the Social Security Death Index or by contacting
relatives. The study was approved by the University of
Pennsylvania Institutional Review Board.
Statistical Analysis
Kaplan-Meier analysis was used to determine both
overall survival and disease-free survival (DFS). Overall
survival was defined as the date of initial pulmonary metas-
tasectomy to the date of death or last follow-up. DFS was
calculated from the date of initial pulmonary metastasectomy
to the date of recurrence, last follow-up, or death.
The log-rank test was used to assess survival differ-
ences between groups identified by the following categorical
variables: age at diagnosis of primary site (50 versus 50
years), size of largest pulmonary metastasis (2 cm versus
2 cm), number of pulmonary metastases (2 versus 2
metastases), histological variant (malignant fibrous histiocy-
toma [MFH] versus other), recurrence at primary site (no
versus yes), extrapulmonary disease before pulmonary in-
volvement (no versus yes), hilar or mediastinal lymph node
involvement (no versus yes), margin status at pulmonary
resection (negative versus positive), use of adjuvant chemo-
therapy for pulmonary disease (no versus yes), type of che-
motherapy regimen (D/I based versus other), date of pulmo-
nary metastasectomy (before 2001 versus 2001 or after), and
surgical approach (thoracoscopic versus open resection).
Univariate Cox regression analysis was used to exam-
ine the relationship of overall survival and DFS with the
following continuous variables: size of largest pulmonary
metastasis, age at diagnosis of primary site, and DFI (only as
a predictor of overall survival and defined as the period from
resection of the primary tumor until initial documentation of
metastases).
Multivariate Cox regression analysis was used to eval-
uate the independent predictive value of variables for overall
survival and DFS. Variables with a p value less than 0.20
found in log-rank or univariate analyses were included in the
final multivariate models. Statistical analyses were performed
using SPSS version 16.0 (SPSS, Inc. Chicago, IL).
Results are expressed as mean (standard deviation)
unless otherwise noted. Because of the modest sample size
and the exploratory nature of our analysis, p less than 0.10
was considered to be statistically significant.
RESULTS
Patient Information
Between 1995 and 2007, 56 patients underwent pulmo-
nary metastasectomy for STS within UPHS, 48 of whom
were included for analysis. Twenty-two (45.8%) were men
and 26 (54.2%) were women. Mean age at diagnosis at the
primary site was 47.9 (15.4) years (range: 12–72 years).
Population characteristics and distribution of tumor
variants are listed in Tables 1 and 2, respectively.
Procedures and Findings
A total of 89 metastasectomies were performed in the
48 patients. Eighteen patients underwent a single pulmonary
resection, 23 underwent a total of two resections, four under-
went three resections, two underwent four resections, and a
single patient underwent five resections. Of the 48 patients,
five patients underwent an initial bilateral procedure by me-
dian sternotomy, four patients underwent initial staged bilat-
eral thoracotomies several weeks apart, and 13 patients (all
with less than three nodules on preoperative imaging) under-
went video-assisted thoracoscopic surgery (VATS) resection.
There were no perioperative deaths.
The mean number of nodules on computed tomography
(CT) before initial resection was 1.6 (1.2); the mean number
of pathologically proven nodules was 2.3 (2.2) (p  0.08).
The range for both nodules on CT and pathologically proven
nodules was 1 to 12.
Overall Survival
Median overall survival after pulmonary metastasec-
tomy was 5.3 years. Three-year and 5-year overall survival
was 67% and 52%, respectively (Figure 1). By univariate
analysis, variables significantly associated with increased
overall survival included 2 pulmonary metastases (p 
0.03), largest pulmonary metastasis 2 cm (p  0.09), and
the absence of extrapulmonary metastases (p  0.10). Other
categorical and continuous variables did not significantly
influence overall survival and are further described in Tables
3 and 4. No variables were found to be significantly associ-
ated with overall survival in multivariate Cox regression
models (Table 5).
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Disease-Free Survival
Median DFS after pulmonary metastasectomy was 1.7
years. Three and 5-year DFS were 17% and 10%, respec-
tively (Figure 2). Increased DFS was associated with smaller
size of the largest pulmonary metastases (p  0.06) and the
absence of extrapulmonary metastases (p  0.07). Other
categorical and continuous variables did not significantly
impact DFS and are detailed in Tables 3 and 4. No factors
significantly predict DFS when analyzed using multivariate
analysis (Table 5).
Adjuvant Chemotherapy
Of the 48 patients analyzed, 31 patients (64.6%) re-
ceived chemotherapy as an adjuvant to pulmonary metasta-
sectomy. Twenty patients received D/I-based regimen,
whereas six patients received chemotherapy regimens includ-
ing vincristine, gemcitabine, docetaxel, carboplatin, and eto-
poside. Five patients received chemotherapy protocols that
were undetermined.
Seven of the 15 patients (46.7%) undergoing pulmonary
metastasectomy before 2001 received adjuvant chemotherapy
versus 24 of 34 patients (72.2%) undergoing metastasectomy
during or after 2001 (p  0.10). Among those receiving che-
motherapy before 2001, three patients (42.8%) received a D/I-
TABLE 1. Characteristics of 48 Patients Undergoing
Pulmonary Metastasectomy for STS
Variables N Percentage
Age at diagnosis
50 yr 23 47.9
50 yr 25 52.1
Size of largest pulmonary metastasisa
2 cm 36 75.0
2 cm 8 16.7
Number of pulmonary metastases confirmed by
pathology reporta
2 metastases 28 58.3
2 metastases 16 33.3
Histologic type
Other 35 72.9
MFH 13 27.1
Recurrence at primary site before pulmonary
metastases
No 43 89.6
Yes 5 10.4
Extrapulmonary metastases before pulmonary
metastases
No 42 87.5
Yes 6 12.5
Hilar or mediastinal lymph node involvement
No 46 95.8
Yes 2 4.2
Date of surgery
Before 2001 15 31.3
2001 or after 33 68.8
Marginsa
Negative 37 82.2
Positive 7 14.5
Received adjuvant chemotherapy
Yes 31 64.6
No 17 35.4
Chemotherapy regimena,b
Other 6 12.5
D/I combination 20 41.7
Surgical approach
VATS 13 27.1
Open resection 35 72.9
a Percentages may not sum to 100% due to missing data.
b Undetermined regimens were not included in analysis.
STS, soft tissue sarcoma; D/I, doxorubicin-ifosfamide; MFH, malignant fibrous
histiocytoma.
TABLE 2. Tumor Histologies
Histologic Variants No. of Patients
Malignant fibrous histiocytoma (MFH) 13
Leiomyosarcoma 9
Synovial sarcoma 6
Liposarcoma 4
Ewing’s sarcoma 2
Gastrointestinal stromal tumor (GIST) 2
Dermatofibrosarcoma 2
Neurofibrosarcoma 1
Hemangiosarcoma 1
Epithelioid sarcoma 1
Clear cell sarcoma 1
Endometrial sarcoma 1
Undetermineda 5
a Undetermined describes histologically confirmed soft tissue sarcoma (STS) lung
metastases that could not be categorized. Primary site histology was unavailable at the
time of analysis.
FIGURE 1. Kaplan-Meier curve of overall survival after pul-
monary metastasectomy for soft tissue sarcoma. Three-year
survival and 5-year survival were 67% and 52%, respectively.
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based regimen, whereas 17 patients (70.8%) received a
D/I-based regimen during or after 2001 (p  0.21).
Median overall survival did not differ between the 31
patients receiving chemotherapy and the 17 patients not
receiving chemotherapy (5.3 versus 4.9 years, respectively;
p  0.82). Three-year and 5-year survival rates for patients
receiving chemotherapy were 63% and 56%, respectively,
versus 74% and 45% for the nonchemotherapy group (Figure
3). Further, no survival differences existed between patients
receiving D/I-based regimen versus patients receiving “other”
regimens (Table 6).
Median DFS for those receiving chemotherapy was 1.1
years versus 1.2 years for those who did not (p  0.88).
Three-year and 5-year Kaplan-Meier DFS for the chemother-
apy group were 18% and 9%, respectively, when compared
with 10% and 10% for the nonchemotherapy group (Figure
4). There was no difference in DFS among those receiving
the D/I-based regimen versus those receiving alternative
regimens (Table 6).
DISCUSSION
The lung is the most common site for distant metastases
of STS. Isolated pulmonary metastases occur in 25 to 50% of
these patients.22 This is a result of these tumors’ propensity to
spread hematogenously, the filtering nature of the extensive
pulmonary capillary bed which metastatic cells originating
from extremities and the pelvis first encounter,21,24 and in-
completely understood mechanisms that favor lodging of
metastases from certain tumor sites to specific metastatic
sites. With this in mind, pulmonary metastasectomy was
conceived to offer patients with pulmonary disease an oppor-
tunity to achieve long-term survival. Several reports have
demonstrated both cost-effectiveness25 and long-term out-
come benefits of pulmonary metastasectomy for patients with
STS.2,4,6,7,11,12,14,26,27 These reports have described 5-year
overall survival rates ranging from 15 to 40%, which com-
pare with 10 to 20% in patients who do not undergo
metastasectomy.5,8–14 Our 5-year overall survival rate of 52%
is, to our knowledge, the highest reported survival rate after
pulmonary metastasectomy for STS and further supports the
role of metastasectomy in properly selected patients.
In our study, factors associated with improved survival
on univariate analysis included having two or fewer pulmo-
nary lesions at the time of resection, having a largest pulmo-
nary lesion smaller than 2 cm, and having no extrapulmonary
metastases. The strongest prognostic variable found in our
series was two or fewer pulmonary lesions at resection. The
significance of fewer metastatic lesions has been described in
several other reports. Nevertheless, the number beyond which
one should hesitate to operate remains unclear.11,26,28,29 Oth-
ers have also found that size of the largest metastasis and
extrapulmonary disease are important variables.11,22,23 In our
study, none of these factors showed statistical significance on
multivariate analysis.
The importance of negative margins, prolonged DFI,
MFH histology, and an age less than 50 years at time of
resection has also been reported, but these were not found to be
significant in our study even on univariate analysis.2,5,6,10–14,26,30
It is possible that the failure to reach statistical significance on at
least some of these variables was due to our relatively smaller
sample size (two of the largest published studies have included
greater than 130 patients).11,22
Despite observing a substantially higher overall sur-
vival than previously reported, DFS remained rare in our
study population. Only 10% of our patients remained alive
without disease at 5 years. These findings suggest that ag-
gressive resection of pulmonary metastases from STS, though
TABLE 3. Log-Rank Analysis of Overall Survival and
Disease-Free Survival after Pulmonary Metastasectomy
Categorical Variables
Overall Survival
Disease-Free
Survival
Median
Survival
(yr) p
Median
Survival
(yr) p
Age at diagnosis
50 yr 5.3 0.70 1.7 0.77
50 yr 4.9 1.7
Size of largest pulmonary
metastasisa
2 cm 5.8 0.09a 1.7 0.14
2 cm 2.3 0.8
Number of pulmonary
metastases confirmed by
pathologya
2 metastases 6.2 0.03a 1.3 0.39
2 metastases 2.3 1.7
Histologic type
MFH 6.2 0.28 1.7 0.88
Other 4.9 0.9
Recurrence at primary site
before pulmonary
metastases
No 4.9 0.52 1.7 0.26
Yes 3.7 0.5
Extrapulmonary metastases
before pulmonary
metastasesa
No 5.8 0.10a 1.7 0.07a
Yes 2.5 1.3
Hilar or mediastinal lymph
node involvement
No 5.3 0.49 1.7 0.93
Yes 4.9 1.3
Date of surgery
Before 2001 4.7 0.41 2.0 0.98
2001 or after 4.4 1.3
Margins
Negative 4.0 0.33 0.9 0.99
Positive 3.2 0.9
Surgical approach
VATS 5.6 0.41 1.5 0.46
Open resection 4.8 1.1
aA statistically significant variable related to overall survival or disease-free
survival.
MFH, malignant fibrous histiocytoma.
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rarely curative, has the potential to convert this disease to what
might be considered a chronic state. It seems that micrometas-
tases often elude even a comprehensive preoperative evaluation
and manual palpation of the lung at the time of resection. Our
study supports previous work emphasizing the value of intraop-
erative evaluation,31 as we found that the number of pathologi-
cally proven metastases was significantly higher than the num-
ber of nodules noted on preoperative CT. Factors associated with
increased DFS on univariate analysis were smaller size of the
largest pulmonary metastases and the absence of extrapulmo-
nary metastases. Neither of these variables was found to influ-
ence DFS on multivariate analysis.
TABLE 4. Univariate Cox Regression Analyses of Overall Survival and Disease-Free Survival after
Pulmonary Metastasectomy
Continuous Variables
Overall Survival Disease-Free Survival
Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Disease-free interval (yr) 0.96 0.80–1.15 0.67 — — —
Size of largest pulmonary metastasis (cm)a 1.17 0.89–1.53 0.27 1.26 0.99–1.62 0.06a
Age (yr) 1.01 0.98–1.04 0.48 1.02 0.99–1.04 0.19
a A statistically significant variable related to overall survival or disease-free survival.
CI, confidence interval.
TABLE 5. Multivariate Cox Regression Analyses of Factors Influencing Overall Survival and
Disease-Free Survival
Variables
Overall Survival Disease-Free Survival
Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Size of largest pulmonary metastasis, 2 cm
vs. 2 cma
3.70 0.68–20.01 0.13 — — —
Number of pulmonary metastases on pathology,
2 metastases vs. 2 metastasesa
2.37 0.64–8.78 0.20 — — —
Extrapulmonary metastases before lung, yes vs. noa 0.80 0.10–6.29 0.83 1.79 0.49–6.50 0.38
Size of largest pulmonary metastasis (cm) — — — 1.23 0.91–1.70 0.17
Age (yr) — — — 1.02 0.99–1.05 0.28
a Reference group.
CI, confidence interval.
FIGURE 2. Kaplan-Meier curve of disease-free survival after
pulmonary metastasectomy for soft tissue sarcoma. Three-
year and 5-year survivals were 17% and 10%, respectively. FIGURE 3. Kaplan-Meier curve of overall survival after pul-
monary metastasectomy for soft tissue sarcoma with adju-
vant chemotherapy versus no chemotherapy (p  0.82).
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Interestingly, seven patients underwent three or more
resections, three of whom achieved long-term survival of 5
years, 8 years, and 12 years, respectively. The latter two
patients remain alive without evidence of disease. The poten-
tial value of “repeat resections” has also been appreciated and
described by Liebl et al. and Weiser et al.32,33 It is our practice
to follow these patients with chest CT every 6 months for a
total of 5 years from their last pulmonary resection. If
resectable disease confined to the chest recurs and remains
limited on a 3-month interval scan, we have no hesitation to
perform repeat metastasectomy.
Historically, survival after pulmonary metastasectomy
for STS has been lower than for OS. Potential explanations
for the reduced impact of metastasectomy in STS versus OS
are (1) the historical lack of equally effective chemothera-
peutic agents for STS as an adjuvant to metastasectomy,21 (2)
the more common occurrence of extrapulmonary metastases
in STS versus OS, and (3) the greater ease of palpating
rock-hard OS metastases versus softer STS metastases at the
time of resection. We believe that there is some validity to the
second and third of these explanations, although we present
no data herein to support these. Regarding the first possible
explanation, advances in adjuvant chemotherapy protocols
for STS have been made over the last 20 years, and D/I-based
regimen has emerged as first-line therapy for systemic dis-
ease.22 The value of their use in conjunction with pulmonary
metastasectomy, however, remains controversial.2,12,20,22,25,30
In our study, increased use over time of both adjuvant
chemotherapy generally and D/I-based regimens specifically
was noted. We were not able to demonstrate, however, a
significant impact of the addition of chemotherapy to the
surgical procedure. It is important to evaluate these results
understanding that disease extent, histology, and grade all
played roles in dictating the decision over whether to add
adjuvant chemotherapy. These may, therefore, have acted as
confounders in the analysis. To properly evaluate the role of
adjuvant chemotherapy, large-scale randomized studies
would likely be necessary.
Finally, to support the hypothesis that our improved
survival results after pulmonary metastasectomy for STS are
due to more stringent patient selection, we have carried out a
semiquantitative analysis comparing the patients included in
our study with those reported in the two largest studies to
date.11,22 Despite slight variations in data representation, this
comparison reveals that fewer patients included in our study
had several (three or more) pulmonary metastases at the time
of metastasectomy 27% in our study versus 51% in the report
by Choong et al.11 Also, 14% of our patients were found to
have greater than five metastases versus 18% in a recent
series published by Canter et al.22 In addition to number of
metastases, fewer patients in our study had large (2 cm in
diameter) pulmonary metastases. Of our patients, 25% had a
nodule larger than 2 cm versus 51% in the report by Choong
et al.11 Furthermore, 11% our patients had a nodule larger
than 5 cm in diameter versus 18% in the report by Canter et
al.22 Given these findings, it does, in fact, seem that stricter
patient selection is a likely explanation of the improved
survival after metastasectomy for STS that we have seen.
CONCLUSION
We present the longest 5-year overall survival rate
published to date for pulmonary metastasectomy in STS.
Although our data show that this procedure rarely provides a
cure, it does seem to convert this process to what might be
considered a chronic disease, with even 8-year survival rates
approximating 40%. As it is difficult to show the definitive
value of prognostic factors, we believe that any patient with
isolated pulmonary disease that has a high chance of under-
going a complete resection without a severe impact on quality
of life should be offered resection. There seems to be little
doubt, however, that those with smaller and fewer metastases
and without prior extrapulmonary metastases (even if con-
trolled) have a greater chance of prolonged survival. Despite
increased use, we are unable to demonstrate that even the
TABLE 6. Log-Rank Analysis of Overall Survival and
Disease-Free Survival after Pulmonary Metastasectomy with
Respect to Chemotherapy Regimen
Chemotherapy Regimen
Overall Survival
Disease-Free
Survival
Median
Survival
(yr) p
Median
Survival
(yr) p
No chemotherapy 4.9 0.41 1.1 0.73
Adjuvant chemotherapya 5.3 1.2
D/I-based chemotherapy 5.3 0.98 0.9 0.42
“Other” chemotherapyb 5.8 1.2
a Includes survival data of all patients receiving adjuvant chemotherapy.
b Includes only survival data of patients with known chemotherapy regimen.
D/I, doxorubicin-ifosfamide.
FIGURE 4. Kaplan-Meier curve of disease-free survival after
pulmonary metastasectomy for soft tissue sarcoma with ad-
juvant chemotherapy versus no chemotherapy (p  0.88).
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most current adjuvant chemotherapy regimens increase sur-
vival beyond resection alone. Nevertheless, to definitely dem-
onstrate the value of metastasectomy or of chemotherapy,
prospective study would be required.
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